Influenza diagnostics Market by Type ( Molecular Diagnostic Tests, Traditional Diagnostic Tests ); End User ( Reference Laboratories, Hospitals/Clinical Laboratories, Other End Users) and Geography: Global Market Size Estimates and Forecast (2022-2030)

The market crossed US$ 1.0 billion mark in 2022 and is expected to hit US$ 2.5 billion by 2030, recording a CAGR of 8.0% during the forecast period.

Influenza diagnostics market has been significantly growing with the growing research in diagnostic technologies.

The increasing prevalence of influenza worldwide has increased the research and development activities towards its effective detection and diagnosis. Most research activity focuses on developing faster and more accurate diagnostic solutions for influenza viruses leading to market growth. The test kits and reagents segment accounted for the largest share of the influenza diagnostics market in 2020, mainly due to the increasing prevalence of influenza and rising demand for rapid disease diagnosis.

Within the report, the market is segmented into type, end-user, and geography. By type, the market is further bifurcated into molecular diagnostic tests and traditional diagnostic tests. Based on end-user, the market is divided into reference laboratories, hospital/clinical laboratories, and other end users. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Advancements in proteomics and genomics will power the growth of futuristic innovations.

Influenza, usually called as "the flu", is an infectious disease caused by influenza. Various traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Nowadays, advanced technologies provide highly effective and accurate diagnoses of influenza. For instance, the reverse transcription-polymerase chain reaction (RT-PCR), or real-time molecular test, affords detection of influenza genetic material.

Completing the human genome project has generated a huge amount of data, resulting in the development of many assays and technologies useful for diagnosing and managing influenza infections. These novel technologies, founded on genomic techniques (such as PCR-based) and proteomics (such as microarray-based detection), help find new influenza viruses. They also allow better surveillance and rapid detection of infectious diseases, serving as an opportunity for the market.  

Growing awareness regarding early diagnosis is one of the major factors accelerating market growth.

The early diagnosis of influenza infection can lead to better treatment. The increasing awareness among the global population regarding the importance of early disease detection is a key factor for the growth of the global influenza diagnostics market. Due to this, organizations are taking initiatives to promote early diagnosis practices to prevent and eradicate mortality due to the disease. For instance, in 2019, Public Health England (PHE) launched a 5-year (2020 to 2025) infectious disease strategy (which includes influenza) to prevent, detect, respond, and reduce the impact of infectious diseases.  

Recent strategic developments in influenza diagnostics market

The influenza diagnostics discovery market has undergone several significant developments, and a few of these have been mentioned below:

• In May 2021 Becton, Dickinson and Company received FDA approval for the BD Veritor Plus System, which is used to diagnose SARS-CoV-2, influenza A, and influenza B.
• In March 2021, Abbott Laboratories, Inc. gained emergency use authorization (EUA) from the FDA for a laboratory PCR assay that diagnose and distinguishes SARS-COV-2, flu A, flu B, and RSV in one test.
• In February 2021, Becton, Dickinson and Company gained emergency use authorization (EUA) from FDA for a new molecular indicative test for both SARS-CoV-2 and influenza A+B.

Several players drive the influenza diagnostics market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Danaher Corporation , Siemens Healthineers, Thermo Fisher Scientific, Inc., F. Hoffmann-LA Roche AG, Abbott Laboratories, Inc., Hologic, Inc., bioMérieux SA are among the prominent players operating in the market.

Target audience for the report:

• Drug developing companies
• Contract development and manufacturing organization,
• Drug discovery-related associations, organizations, forums, and alliances
• Government bodies, such as regulating authorities and policymakers
• Venture capitalists, private equity firms, and start-up companies
• Drug distributors and sales firms
• End users of drug discovery
• Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

• Type:
  • Molecular diagnostic tests
  • Traditional diagnostic test
• End User:
  • Reference laboratories
  • Hospital/Clinical laboratories
  • Other end users
• Region
  • North America
  • Europe
  • Asia Pacific (APAC)
  • South & Central America
  • Middle East & Africa
• Companies profiled
  • Abbott
  • Quidel Corporation
  • BioMérieux
  • BD
  • F. Hoffmann-La Roche Ltd
  • Oxford Biosystems
  • Thermo Fisher Scientific
  • Meridian Bioscience
  • Cepheid
  • altona Diagnostics GmbH

Companies profiled
- Abbott
- Quidel Corporation
- BioM?rieux
- BD
- F. Hoffmann-La Roche Ltd
- Oxford Biosystems
- Thermo Fisher Scientific
- Meridian Bioscience
- Cepheid
- altona Diagnostics GmbH